• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact

    8/13/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce.

    FAIRFIELD, N.J., Aug. 13, 2025 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced the recipients of its 2025 Advancement, Commitment, and Engagement (ACE) Awards, honoring high-impact programs that are redefining workforce development across the healthcare industry. The ACE Awards recognize standout programs with bold strategies that prioritize people, scale globally, deliver measurable business and social outcomes, and honor the future of leadership and innovation in healthcare. This year's honorees include:

    Healthcare Businesswomen's Association (PRNewsfoto/Healthcare Businesswomen's Association)

    • AstraZeneca, Young Health Programme (YHP), 2025 ACE Award
    • Viseven, Expert Communities and Unicorns Recognition Program, 2025 ACE Aspire Award

    "The ACE Awards highlight leadership that redefines workforce development in healthcare," said Mary Stutts, CEO of the Healthcare Businesswomen's Association. "AstraZeneca and Viseven have both demonstrated how strategic, purpose-driven programs can empower talent, foster innovation, and generate meaningful business outcomes. This level of commitment to people-centered growth is essential for advancing the entire healthcare ecosystem."

    About AstraZeneca's Young Health Programme (YHP)

    The HBA ACE Award honors established programs that have demonstrated measurable success in engagement, innovation, and workforce development. AstraZeneca was recognized with the 2025 ACE Award for its long-standing Young Health Programme (YHP), a global health equity initiative focused on the prevention of non-communicable diseases (NCDs) – including cancer, diabetes, heart disease and respiratory disease – while also cultivating purpose-driven leadership among employees.

    Celebrating its 15th year, the YHP is a community-driven program that seeks to advance health equity by activating underserved youth to reduce their risk of NCDs through peer education, local partnerships, and youth advocacy. To date, the initiative has directly reached more than 20 million young people across more than 40 countries in partnership with more than 60 not-for-profit organizations, including UNICEF and Plan International, while also mobilizing 20,000 AstraZeneca employees who have contributed nearly 100,000 hours of volunteer service.

    YHP not only tackles critical global health challenges, but it strengthens AstraZeneca's internal culture by connecting employees to meaningful work and volunteering opportunities that extend beyond their day-to-day roles. The program, through its youth leaders, has positively influenced 18 NCD prevention-related policies worldwide and continues to create leadership pathways for both youth and employees, driving sustainable impact across communities and within the company itself.

    "We are honored to receive the HBA ACE Award for the Young Health Programme," said Marc Dunoyer, Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca and Young Health Programme Senior Executive Team Sponsor. "The Young Health Programme demonstrates our commitment to communities and truly reflects our corporate values. By focusing on prevention and supporting young people to make informed health choices, YHP is helping to shape healthier futures – a transformative approach that will have a lasting impact for generations to come."

    About Viseven's Expert Communities and Unicorns Recognition Program

    The HBA ACE Aspire Award honors emerging programs that demonstrate strong early outcomes and the potential for lasting impact. Viseven was selected as the 2025 Aspire Award recipient for its Expert Communities and Unicorns Recognition Program – a newly launched initiative transforming how the company fosters internal engagement, collaboration, and culture.

    Introduced in 2024, the program consists of two core components: Expert Communities, which promote cross-functional learning and professional development in key areas like project management, finance, and client engagement; and the Unicorns Recognition Program, a gamified platform where employees award "UniCoins" to peers who exemplify Viseven's core values: passion, agility, curiosity, and empathy.

    With more than 700 employees engaged to date, these initiatives are surfacing internal talent, enhancing peer connection, and building a scalable culture of innovation, appreciation, and shared growth – setting a powerful foundation for long-term organizational success.

    "We are incredibly honored to receive the 2025 ACE Aspire Award from the HBA," said Nataliya Andreychuck, CEO and Co-founder, Viseven. "At Viseven, we believe that sustainable growth begins with a strong internal culture. The Expert Communities and Unicorns Recognition Program is our way of investing in people – empowering them to lead, grow, and innovate together. This recognition affirms that putting people at the center of transformation isn't just the right thing to do – it's also how we build the future of healthcare."

    Event Details and Contact

    The HBA will honor both AstraZeneca and Viseven during the 2025 HBA Annual Conference, hosted in Las Vegas, Nevada, from 29 September through 1 October. For inquiries about media passes to the HBA's 2025 Annual Conference, interview opportunities, or information about the HBA's signature award programs, please contact Hannah McKee, Senior Manager of Communications & Media Relations, at [email protected].

    About the Healthcare Businesswomen's Association (HBA)

    The Healthcare Businesswomen's Association (HBA) is a global leadership accelerator, talent pipeline, and business growth partner for the healthcare industry. With a presence spanning 80 locations, the HBA supports more than 150 Corporate Partners and impacts a workforce of nearly six million employees. The HBA empowers healthcare leaders at every stage of their careers through global forums, programs that prepare the future healthcare workforce, and recognition initiatives celebrating outstanding individuals and organizations.

    About AstraZeneca

    AstraZeneca (NASDAQ:AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. For details on how to contact the Investor Relations Team, please click here. For Media contacts, please here.

    About Viseven

    Viseven enables global life sciences organizations to deliver compliant and impactful experiences to HCPs & Patients through a scalable end-to end solution that covers strategy, operational excellence, and technology enablement.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-healthcare-businesswomens-association-hba-honors-astrazeneca-and-viseven-with-2025-ace-awards-for-workforce-innovation-and-global-impact-302528387.html

    SOURCE Healthcare Businesswomen's Association

    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/18/25 11:07:43 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/15/25 10:40:25 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/12/25 10:45:07 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca upgraded by UBS

    UBS upgraded AstraZeneca from Neutral to Buy

    2/13/25 8:39:12 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on AstraZeneca

    Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

    2/12/25 6:59:42 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery

    AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815310613/en/ Initially approved by the Food and Drug Admin

    8/15/25 8:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact

    The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J., Aug. 13, 2025 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced the recipients of its 2025 Advancement, Commitment, and Engagement (ACE) Awards, honoring high-impact programs that are redefining workforce development across the healthcare industry. The ACE Awards recognize standout programs with bold strategies that prioritize people, scale globally, deliver measurable business and social outcomes, and honor the future of leadership and innovation in healthcare. This year's honorees include:

    8/13/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG)

    The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris (ravulizumab) for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) and adult patients with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (gMG). With the agreement in place with the pCPA, individual provinces and territories may now initiate the p

    8/7/25 8:05:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

    In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

    2/26/24 9:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/4/22 9:06:48 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/3/21 1:13:21 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Financials

    Live finance-specific insights

    View All

    AstraZeneca results: H1 and Q2 2025

    Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

    7/29/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

    Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. There are 1.3 billion people worldwide livin

    7/14/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca's Q1 2025 Financial Results

    Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

    4/29/25 2:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care